Becton, Dickinson and Company (LON:0R19)
173.41
+4.64 (2.75%)
At close: May 12, 2025
LON:0R19 Revenue
Becton, Dickinson and Company had revenue of $5.27B USD in the quarter ending March 31, 2025, with 4.50% growth. This brings the company's revenue in the last twelve months to $20.87B, up 5.84% year-over-year. In the fiscal year ending September 30, 2024, Becton, Dickinson and Company had annual revenue of $20.18B with 4.16% growth.
Revenue (ttm)
$20.87B
Revenue Growth
+5.84%
P/S Ratio
2.36
Revenue / Employee
$281.99K
Employees
74,000
Market Cap
38.04B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 20.18B | 806.00M | 4.16% |
Sep 30, 2023 | 19.37B | 502.00M | 2.66% |
Sep 30, 2022 | 18.87B | -261.00M | -1.36% |
Sep 30, 2021 | 19.13B | 3.06B | 19.02% |
Sep 30, 2020 | 16.07B | -1.22B | -7.03% |
Sep 30, 2019 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 30, 2016 | Pro | Pro | Pro |
Sep 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
Becton, Dickinson and Company News
- 21 hours ago - BD to Announce Financial Results for its Third Quarter of Fiscal 2025 - PRNewsWire
- 4 days ago - The Best Health Care Stocks to Buy - Kiplinger
- 6 days ago - Buy 3 "Safer" Dividend Kings Of 25 From May's 55 - Seeking Alpha
- 8 days ago - Block, Becton Dickinson And Pilgrim's Pride Are Among Top 10 Large-Cap Losers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? - Benzinga
- 10 days ago - Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years - Benzinga
- 10 days ago - Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years - Benzinga
- 10 days ago - Becton, Dickinson downgraded at more firms following Q2 results - Seeking Alpha
- 10 days ago - Stock Of The Day – Bullish Capitulation In Becton, Dickinson? - Benzinga